<DOC>
	<DOCNO>NCT00906399</DOCNO>
	<brief_summary>The primary objective study determine efficacy peginterferon beta-1a reduce annualized relapse rate ( ARR ) participant relapse multiple sclerosis ( RMS ) 1 year . The secondary objective study determine whether peginterferon beta-1a , 1 year compare placebo , effective reduce total number new newly enlarge T2 hyperintense lesion brain magnetic resonance imaging ( MRI ) scan , reduce proportion participant relapse , slow progression disability .</brief_summary>
	<brief_title>Efficacy Safety Study Peginterferon Beta-1a Participants With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>This global multicenter , randomize , double-blind , parallel-group , placebo-controlled study . The treatment period 96 week ( 2 year ) duration . Treatment Year 1 ( Week 0 Week 48 ) refer placebo-controlled treatment period study . At begin Treatment Year 1 , participant randomize receive placebo , peginterferon beta-1a 125 μg every 2 week , peginterferon beta-1a 125 μg every 4 week . At end Treatment Year 1 , participant placebo group re-randomized receive peginterferon beta-1a treatment treatment Year 2 ( Weeks 48 Week 96 ) participant receive peginterferon beta-1a 125 μg every 2 every 4 week . Per protocol , primary secondary endpoint pertain Year 1 data .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Must confirm diagnosis relapse multiple sclerosis ( RMS ) , define McDonald criterion 1 4 ( Polman , 2005 ) Must EDSS score 0.0 5.0 . Must experience least 2 relapse medically document within last 3 year least one occur last 12 month Key Other chronic disease immune system , malignancy , urologic , pulmonary , gastrointestinal disease Pregnant nursing woman Prior treatment interferon could exceed 4 week subject must discontinue interferon treatment 6 month prior Baseline NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>interferon</keyword>
	<keyword>injectable</keyword>
	<keyword>MS</keyword>
	<keyword>SC</keyword>
	<keyword>PEGylated</keyword>
	<keyword>Interferon beta-1a</keyword>
	<keyword>relapse</keyword>
	<keyword>PEG</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>subcutaneous</keyword>
</DOC>